Assessment of Bone Scintigraphy Results and Its Clinical Indications and Determinants in Prostate Cancer Patients at CHU Bab El Oued, Algiers, Algeria
No Thumbnail Available
Date
2025-03-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Addis Ababa University
Abstract
Background Prostate cancer is a leading malignancy among men worldwide, with bone
metastases being a critical factor in disease progression and patient prognosis. Bone scintigraphy
is a widely used imaging technique for detecting bone metastases, but its clinical utility varies
based on patient characteristics. This study evaluates the clinical indicators influencing bone
scintigraphy outcomes in prostate cancer patients at CHU Bab El Oued, Algiers, Algeria.
Objective To investigate the clinical indications and determinants influencing the use of bone
scintigraphy in prostate cancer patients at CHU Bab El Oued.
Methods A retrospective observational study was conducted on 354 prostate cancer patients who
underwent bone scintigraphy at CHU Bab El Oued. Descriptive statistics, Chi-Square tests, logistic
regression, and ROC curve analysis were used to examine associations between PSA levels,
Gleason scores, age, and bone scintigraphy results.
Results Of the 354 patients studied, 32.2% of patients had positive bone scintigraphy results,
indicating metastasis. Higher PSA levels (>20 ng/mL) and Gleason scores (≥8) were significantly
associated with positive bone scans (p < 0.001). Age was not a significant predictor of metastasis
(p = 0.691). Logistic regression analysis confirmed PSA and Gleason scores as key predictors of
metastasis, with higher Gleason scores increasing the risk by 2.26 times (OR = 2.266, p < 0.001).
The ROC curve showed strong predictive ability (AUC = 0.89), suggesting high accuracy in
predicting bone metastases.
Conclusion Bone scintigraphy is indicated for prostate cancer patients with specific high-risk
features to detect bone metastases effectively. Specifically, PSA levels and Gleason scores are
strong predictors of bone metastases, with higher values (PSA >20 ng/mL and Gleason score ≥8)
significantly increasing the likelihood of positive findings, while age alone does not play a
significant role. The predictive model demonstrated high accuracy, reinforcing the need for
targeted use of bone scintigraphy in high-risk patients to optimize clinical decision-making.
Description
Keywords
Prostate Cancer, Bone Scintigraphy, PSA Levels, Gleason Score, Bone Metastases